<DOC>
	<DOCNO>NCT00024674</DOCNO>
	<brief_summary>Although Neopharm terminate sponsorship study , continue sponsorship NCI . Please see `` Experimental Drug SS1 ( dsFv ) -PE38 Treat Cancer '' ( Study ID number 010011 ) . SS1 ( dsFv ) -PE38 oncology drug product contain bacteria toxin , fuse high affinity , disulfide stabilize antibody . The fused protein retain cell kill activity , bind cell express mesothelin . Tumors characterize high surface mesothelin expression include mesothelioma ; epithelial carcinoma ovary peritoneum ; squamous cancer cervix upper aerodigestive tract , include esophagus , head , neck cancer . This dose-escalating study determine maximum tolerate dose ( MTD ) intravenous SS1 ( dsFv ) -PE38 administer continuously 10 day every four week maximum four course treatment . Dose escalation proceed cohort 3 dose-limiting toxicity ( DLT ) observe .</brief_summary>
	<brief_title>Study SS1 ( dsFv ) -PE38 ( SS1P ) Anti-Mesothelin Immunotoxin Advanced Malignancies : Continuous Infusion 10 Days</brief_title>
	<detailed_description>OBJECTIVES : I . Investigate safety efficacy SS1 ( dsFv ) -PE38 administer 10-day continuous intravenous infusion . II . Determine toxicities maximum tolerate dose ( MTD ) SS1 ( dsFv ) -PE38 give continuous intravenous infusion ten day patient advanced malignancy . III . Evaluate response select advanced malignancy continuous intravenous infusion SS1 ( dsFv ) -PE38 ten day dos near MTD . IV . Characterize plasma kinetics SS1 ( dsFv ) -PE38 administer continuous intravenous infusion . V. Determine appearance serum antibody SS1 ( dsFv ) -PE38 . PROTOCOL OUTLINE : To exclude immediate allergic hypersensitivity reaction , patient receive test dose SS1 ( dsFv ) -PE38 , observe 30 minute prior receive continuous infusion Day 1 treatment course . Each treatment give continuous intravenous infusion ten day . After first 24 hour infusion , Investigator 's discretion , patient allow leave hospital day pas per NCI policy . After end infusion patient observe overnight . The first patient dose level must observe development toxicity least 14 day begin treatment additional patient enrol . At least three patient accrue dose level . Dose escalation within patient allow . PROJECTED ACCRUAL : Up 30 patient</detailed_description>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Disease Characteristics Histopathologic diagnosis one follow malignancy : malignant mesothelioma ; ovarian carcinoma , nonmucinous epithelial histology , include primary peritoneal fallopian tube carcinoma ; squamous cell cancer lung ; squamous cell cancer head neck ; squamous cell cancer cervix . Recurrent unresectable disease appropriate definitive therapy . Tumor ( initial recurrent ; least 30 % tumor cell ) must positive ( least 1+ ) mesothelin immunohistochemistry . No concurrent antitumor treatment . At least 4 week since prior antitumor therapy , recovery side effect , least one week since hematopoetic growth factor therapy . Measurable evaluable tumor document within 4 week prior study entry . Patient Characteristics At least 18 year age . At least 12week life expectancy . Performance Status ( ECOG ) 02 . Adequate organ function , include : Absolute neutrophil count least 1,000/mm3 ; Platelets least 75,000/mm3 ; Creatinine , Calcium , total Bilirubin le equal upper limit normal ; Liver enzymes AST ALT less equal 2.5 x upper limit normal ; Albumin least 3.0 g/dL ; Oxygen ( O2 ) saturation great 92 % ( room air ) . Signed Informed Consent , accordance institutional criterion . No known Central Nervous System ( CNS ) spinal cord involvement tumor . No detectable antibody SS1 ( dsFv ) PE38 . No concurrent antitumor therapy . No cardiovascular condition NY Heart Association Grade IIIV , clinicallysignificant pericardial effusion . No infection require parenteral antibiotic ; HIV infection ; seropositivity Hepatitis B Hepatitis C. Not pregnant nursing . Females childbearing potential must use effective method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>SS1 ( dsFv ) -PE38</keyword>
	<keyword>SS1P</keyword>
	<keyword>anti-mesothelin immunotoxin</keyword>
	<keyword>advanced malignancy</keyword>
</DOC>